Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395031 · ClinicalTrials.gov registry record · Phase 2
Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder
A Phase 2 study, sponsored by Manhattan Psychiatric Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00395031 is a Phase 2 study that has completed, run by Manhattan Psychiatric Center. The registered enrollment target is 57 participants.
The verdict
NCT00395031, a Phase 2 study, has completed, sponsored by Manhattan Psychiatric Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The aim of the protocol is to study the effects of 320 mg/day of ziprasidone (Geodon) on glucose and lipid metabolism of patients with both Diabetes Type II (DM) and schizophrenia or schizoaffective disorder, after switching their antipsychotic medication/s from typical and/or atypical to ziprasidone monotherapy.
Interventions
- DRUG Ziprasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2003-09 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00395031
The ClinicalTrials.gov registry entry for NCT00395031 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Manhattan Psychiatric Center, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ziprasidone is the first listed.
NCT00395031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00395031 about?
NCT00395031 is a clinical study titled "Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder". The aim of the protocol is to study the effects of 320 mg/day of ziprasidone (Geodon) on glucose and lipid metabolism of patients with both Diabetes Type II (DM) and schizophrenia or schizoaffective disorder, after switching their antipsychotic medication/s from typical and/or atypical to ziprasidon...
What is the current status of trial NCT00395031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2003-09. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00395031?
The interventions under investigation include: Ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00395031?
This trial is sponsored by Manhattan Psychiatric Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.